Stakeholder involvement

Author(s): 
Last revised: 
2014-06-11

This division presents a selection of publications on stakeholder involvement in Health Technology Assessment (HTA). Regarding the stakeholders "patients" and "public / consumer" separate publication listings are introduced. Please feel free to visit the additional publication listings on
Patient involvement and preferences
Public / consumer involvement

  1. Cavazza M, Jommi C. Stakeholders involvement by HTA organisations: Why is so different? Health Policy 2012; 105(2-3): 236-245. [Further reference details] [Full text]

  2. Cicchetti A, Iacopino V, Carletto A, Marchetti M, Mennini FS. Il ruolo degli stakeholder nel processo di HTA. G Ital Health Technol Assess 2011; 4(2): 69-77. [Further reference details] [Full text]

  3. Flipse SM, van der Sanden MC, Osseweijer P. Setting up spaces for collaboration in industry between researchers from the natural and social sciences. Sci Eng Ethics 2014; 20(1): 7-22. [Further reference details] [Full text]

  4. Frønsdal K1, Pichler F, Mardhani-Bayne L, Henshall C, Røttingen JA, Mørland B, Klemp M. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry. Int J Technol Assess Health Care 2012; 28(4): 374-381. [Further reference details] [Full text]

  5. Hao Y, Thomas A. Health technology assessment and comparative effectiveness research: A pharmaceutical industry perspective. Expert Rev Pharmacoecon Outcomes Res 2013; 13(4): 447-54. [Further reference details] [Full text]

  6. Health Information and Quality Authority. Guidelines for Stakeholder Engagement in Health Technology Assessment in Ireland. Dublin: HIQA; 2014. [Further reference details] [Full text]

  7. Heath I. View of health technology assessment from the swampy lowlands of general practice. Int J Technol Assess Health Care 2004; 20(1): 81-86. [Further reference details] [Full text]

  8. Hivon M, Lehoux P, Denis JL, Tailliez S. Use of health technology assessment in decision making: coresponsibility of users and producers? Int J Technol Assess Health Care 2005; 21(2): 268-275. [Further reference details] [Full text]

  9. Lehoux P, Hivon M, Denis JL, Tailliez S. What medical specialists like and dislike about health technology assessment reports. J Health Serv Res Policy 2009; 14(4): 197-203. [Further reference details] [Full text]

  10. Leung MY, Halpern MT, West ND. Pharmaceutical technology assessment: Perspectives from payers. J Manag Care Pharm 2012; 18(3): 256-264. [Further reference details] [Full text]

  11. Lothgren M, Ratcliffe M. Pharmaceutical industry's perspective on health technology assessment. Int J Technol Assess Health Care 2004; 20(1): 97-101. [Further reference details] [Full text]

  12. McGregor M, Brophy JM. End-user involvement in health technology assessment (HTA) development: A way to increase impact. Int J Technol Assess Health Care 2005; 21(2): 263-267. [Further reference details] [Full text]

  13. Nielsen CP, Lauritsen SW, Kristensen FB, Bistrup ML, Cecchetti A, Turk E, et al. Involving stakeholders and developing a policy for stakeholder involvement in the European network for health technology assessment, EUnetHTA. Int J Technol Assess Health Care 2009; 25(Suppl 2): 84-91. [Further reference details] [Full text]

  14. Rosenbaum SE, Glenton C, Nylund HK, Oxman AD. User testing and stakeholder feedback contributed to the development of understandable and useful Summary of Findings tables for Cochrane reviews. J Clin Epidemiol 2010; 63(6): 607-619. [Further reference details] [Full text]

  15. Schubert F. Health technology assessment: The pharmaceutical industry perspective. Int J Technol Assess Health Care 2002; 18(2): 184-191. [Further reference details] [Full text]

  16. Watkins JB. Payer perspectives on health technology assessment. J Manag Care Pharm 2012; 18(3): 265-267. [Further reference details] [Full text]
Total votes: 1329